|
Jazz Petition Alleges Agency Wrongly Accepted Xyrem ANDA
Jazz Pharmaceuticals is calling on the FDA to rescind its acceptance of Roxane Laboratories’ ANDA for a generic version of Jazz’s narcolepsy drug Xyrem, saying the FDA prematurely accepted the application, violating federal law and harming Jazz and other potential ANDA sponsors.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
FDA Questions Reckitt’s Motives in Petition Denial, OKs Suboxone ANDAsTwo Ex-FDA Commissioners Say Generic Makers Don’t Get Free Pass on State Suits Actavis Hit with Infringement Suit Following Fortesta ANDA Submission FDA Questions Reckitt Benckiser’s Motives in Petition Denial, OKs Two Suboxone Generics
|
Subscribe
Archives